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Type C RNA tumor viruses are known to cause lymphomas or leukemia in lower
mammals and subhuman primates (1, 2) . In certain animals, e.g ., cats, antibody
against virus-associated proteins apparently protects against virus-induced neoplasias
(3, 4) . Nucleic acids and proteins related to components from animal retroviruses have
sometimes been found in fresh and cultured human cells, but the detection and
isolation of discrete particles is a rare event (5-7) . Mammalian type C retroviral
proteins can be immunogenic in man (8), and human antibodies reactive with
retroviral proteins have been reported by several investigators (9-14) . The major
reactivity reported has been against the viral glycoprotein coat (gp70), and there has
been a consistent lack of correlation between antibody titer and a specific pathologic
state . Recently, the existence of human antiviral reactivity has been questioned
because many of the natural antibodies described have been shown to lack specificity
and to cross-react with antigenic determinants present in fetal calf serum and
nonhuman cells (15-17) . The lack of a well-defined human retrovirus has obviously
impeded progress on this issue .
In animals, retroviruses often infect T cells . It was therefore of interest to examine
human T cells for the presence of these viruses . To carry out such analyses, the ability
to grow these cells in culture is essential . After the discovery of T cell growth factor
(TCGF ; 18, 19) 1 it became possible to grow in vitro relatively mature human T cells .
Several novel types of normal and neoplastic T cell lines were established (20, 21) .
Two interesting observations emerged from these studies : (a) many of the neoplastic
T cells from some T cell leukemias and lymphomas respond directly to TCGF,
whereas normal T cells require initial lectin or antigen activation (20, 22, 23), and (b)
the use of purified TCGF (24) is superior to crude fractions in maintaining the growth
of these cells because of the removal of inhibitors as well as the removal of the lectin
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that activates normal T cells . Purified TCGF can therefore be used to culture
neoplastic T cells in the absence of contaminating normal T cells (22) .
Three cell lines established a year apart from two patients with cutaneous T cell
lymphoma and leukemia (CTCL), have expressed type C retrovirus particles called
HTLV, strains CR and MB (25) .2 Analysis of these isolates showed that they are not
significantly related to previous animal retrovirus isolates . These analyses included
the lack of significant nucleic acid homology between HTLV sequences and those of
animal retroviruses (26), lack of detectable immunologic cross-reactivity of the major
core protein (p24) ofHTLV with that ofother retroviruses (27), and lack ofsignificant
antigenic relatedness of the reverse transcriptase purified from HTLV and the reverse
transcriptase of other retroviruses (28) .
The availability of frozen sera from patient CR, whose lymph node-derived cell
line, HUT102, gave rise to HTLVcR (25), provided a unique system with which to
readdress the question of natural antibodies . In this paper, data obtained using two
different assay systems demonstrate : (a) the presence of natural antibodies in the
serum of patient CR directed against the major core proteins ofHTLVcR, and (b) the
specificity of these antibodies for the proteins ofHTLV . Data reported elsewhere have
shown the presence of the major core protein (p24) and nucleotide sequences of
HTLVcR in the primary uncultured leukemic cells of a patient with Sezary T cell
leukemia . 2 Cells obtained from the blood of this patient were those from which
HTLVMB was isolated . The results reported here extend the finding of HTLV
information in primary leukemia cells by providing strong evidence that the virus
was present in patient CR during the course ofhis disease and that viral core proteins
were important in the antibody response .
Materials and Methods
Sera .
￿
Serum samples from patients with CTCL were collected at the Washington Veteran's
Administration Hospital during 1979 . Normal sera were obtained from 55 random donors,
including some laboratory workers .
Viruses and Cells .
￿
Retroviruses used included HTLVcR grown in HUT 102 cells ; HTLVMB,
the second independent viral isolate from a human Sezary syndrome-derived T lymphoblastic
cell line ; the M7 strain of the baboon endogenous virus (BaEV) grown in A204 cells (human
rhabdomyosarcoma) or in A7573 cells (dog thymus) ; the simian sarcoma virus (SSV) grown in
A204 cells ; the Rauscher murine leukemia virus (RLV) grown in JLSV-10 cells (mouse
fibroblasts) ; the cat endogenous virus RD 114, grown in RD cells (human rhabdomyosarcoma) ;
the feline leukemia virus (FeLV), grown in FL-74 cells (feline lymphoblasts) ; the San Francisco
strain of the gibbon ape leukemia virus (GALVsF), grown in NC37 cells (normal human B
lymphoblasts) ; the bovine leukemia virus (BoLV) grown in fetal lamb kidney cells ; and the
avian myeloblastosis virus (AMV) purified from chick plasma provided by Dr. Joseph Beard,
Life Sciences, Inc., Gulfport, Fla . These viruses were disrupted in 50 mM Tris-HCI, pH 7.9,
0.25% Triton X-100, 0.2 mM dithiothreitol (DT-n, 1 mM EDTA, and 1 mM phenylmethyl
sulfonyl fluoride (PMSF), and centrifuged at 80,000 g for 90 min . The solubilized viral proteins
were mixed end over end at 4°C for 2 h with SM-2 biobeads (Bio-Rad Laboratories, Richmond,
Calif.) to remove the detergent (29) . Cells used included normal human T cells obtained by
phytohaemagglutin stimulation of peripheral blood leukocytes for 72 h ; the standard human
T cell lines, Molt-4 andCEM ; the Daudi human B cell line ; the HTLVcR-producing HUT102
line ; and the CTCL-derived transformed but non-virus-producing HUT78 cell line . Cell lysates
were prepared by incubating cell pellets for 1 h at 4°C in 20 mM sodium phosphate buffer, pH
2 Poiesz, B . J ., F . W . Ruscetti, M . S . Reitz, V . S . Kalyanaraman, and R . C . Gallo . Evidence for nucleic
acids and antigens of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sezary
T cell leukemia and isolation of the virus . Manuscript submitted for publication .POSNER ET AL.
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7 .5, containing 0.5% Triton X-100, 0.8 M NaCl, and 1 mM PMSF. Particulate material was
removed by centrifugation at 42,000 g for 30 min. Protein concentrations of perchloric acid-
precipitated samples of solubilized viruses and cell lysates were measured by the method of
Lowry et al. (30).
Solid-Phase Radioimmunoassay.
￿
A modified version of a previously published solid-phase assay
was used for screening the sera (31, 32). For each serum sample to be tested, 100 ng of each
solubilized viral preparation, diluted in 50 /Al of 15 mM NaHC03, 35 mm Na2C03, and pH 9.6
coating buffer (CBC), were added in duplicate to wells of a 96-well Immulon plastic microtiter
plate (Dynatech Laboratories, Inc., Dynatech Corp., Alexandria, Va.). Control wells
of 50 I,1 of 1% bovine serum albumin (BSA) in CBC and 50 I,1 of undiluted fetal calf serum
(FCS) were included for each complete serum assay. After overnight absorption at 4°C,
unbound protein was aspirated and the wells were coated with 1% BSA in CBC for 2 h to block
naked binding sites. The plates were rinsed three times with 0.1% BSA in phosphate-buffered
saline (PBS), and 50 ul of a 1 :75 dilution of a human serum sample diluted in PBS containing
0.5% Tween 20 (PBS-Tween) was added to each well for 1 h at 27°C. Unbound proteins were
aspirated and the wells were washed three times with 0.1% BSA in PBS. Goat anti-human IgG
(N. L. Cappel Laboratories, Inc., Cochranville, Pa.) was purified by affinity chromatography
through a column ofhuman IgG coupled to Sepharose 4B and then iodinated by the chloramine
T method (33) to a specific activity of 800,000 cpm/lAg protein. 50,000 cpm of 1251-goat anti-
human IgG diluted in 50 l,1 of PBS-Tween were added to each well for 1 h at 27 °C. Unbound
radiolabeled detector was removed and the plates were washed 7-10 times with tap water and
dried. The wells were separated on a band saw and counted for 1 min in an LKB 1280
Ultrogamma counter (LKB Instruments, Inc., Rockville, Md.)
Solid-Phase Immunocompetition Assay.
￿
Disrupted viral protein (50 ng of HTLVcR or 100 ng of
BaEV, GALVSF, or FeLV) in 50 1,1 CBC was absorbed to wells of a microtiter plate as for the
solid-phase radioimmunoassay. Sera to be tested were diluted in PBS-Tween to give ^-30% of
maximal binding to the virus on the plate. 50-ltl aliquots of the diluted sera were preincubated
with the indicated amounts of competing protein in 50 lil PBS-Tween for 1 h at room
temperature. Subsequently, 50-j,l aliquots ofthe preincubation mixture were added in duplicate
to the virus-coated microtiter wells. The remainder of the assay proceeded as described for the
solid-phase radioimmunoassay. In the case of competition by cell lysates, a control competition
using cell lysis buffer alone was carried out to correct for possible removal of adsorbed HTLVcR
from the microtiter wells by the Triton X-100. The percent antigen binding was determined by
dividing the value obtained in the presence ofcompeting cellular protein by the value obtained
in the presence of an equivalent volume of lysis buffer.
Radioimmune Precipitation Assay.
￿
Disrupted HTLVcR (20 pg) was extensively dialyzed against
PBS and reacted with 1 mCi of monoiodinated Bolton-Hunter reagent (New England Nuclear,
Boston, Mass.) for 1 h at 4°C. The reaction was terminated by the addition of 0.2 M glycine
and 0.1 M sodium borate, pH 8.5; and the mixture was passed through an 8-ml Bio-Gel p10
column (Bio-Rad Laboratories) previously equilibrated with a buffer of 0.05 M sodium
phosphate, pH 7.5, containing 0.25% gelatin. Fractions were eluted with PBS and collected
into an equal volume of PBS containing 1% BSA. Titration curves were constructed by
incubating .r 150,000 cpm of iodinated HTLVcR proteins (7,500 cpm/ng protein) in 50 ltl of
0.1% gelatin; 300 mM NaCl; 0.2% Triton X-100; 0.01% Tween 80; 10 mM sodium phosphate,
pH 7.5; 0.02% sodium azide (radioimmunoprecipitation [RIP] buffer) with serial twofold
dilutions of serum in RIP buffer. The final volume of the mixture was adjusted to 500 pd with
RIP buffer. After incubation for 16 h at 4°C, the antigen-antibody complexes were precipitated
at 4°C for 24 h by adding sufficient staphylococcal protein A Sepharose (previously swollen in
RIP buffer) in 250 [,1 RIP buffer to give a hydrated bead volume of 10 times the serum volume
added. Precipitates were washed three times with 1-ml portions of RIP buffer and counted in
the gamma counter.
Competition RIP Assay. Sera were diluted in RIP buffer to give -50% precipitation of
iodinated HTLV proteins. Mixtures containing serum, 1251-HTLV proteins, and competing
proteins (either disrupted viruses or cell lysates) were incubated for 16 h at 4°C. Precipitation
of immune complexes and subsequent processing of the precipitates were carried out as for the
radioimmune precipitation assay.336
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Polyacrylamide Gel Electrophoresis .
￿
Samples were electrophoresed on 12% polyacrylamide gels
containing sodium dodecyl sulfate according to the method of Laemmli (34) . 1-mm slices of
each gel were counted in the gamma counter.
Molecular weights were determined by comparing relative mobilities ofHTLVcR proteins to
those of standard proteins, including phosphorylase A, BSA, ovalbumin, chymotrypsinogen,
and ribonuclease .
Results
Reactivity to HTL VcR in CTCL Patient Sera .
￿
The coded sera of 17 patients with
CTCLand 55 normal donors were screened for the presence of antibodies to HTLVcR
and other retroviral proteins by a solid-phase radioimmunoassay (Table I) . Only the
data for the first 20 normal sera assayed are listed individually ; results for the entire
55 are summarized at the bottom of Table I . The purpose of this limited survey was
to determine whether antiviral reactivity could be found in the sera of patients with
CTCL, especially in sera previously collected from the patient CR, and to determine
whether the antibody binding was specific for HTLVcR proteins . Unfortunately, no
serum was available from patient MB, the source of HTLVMB . No attempt was made
to use this series to define the interface between a "positive" and "negative" value .
Two sera, one from the patient CR and a second from patient CTCL-4 (CTCL-17
serum is a second sample from patient CTCL-4), bound strongly to HTLVcR ; patient
CR serum also reacted strongly with HTLVMB (Table I) . The amount of HTLVMB
available was limited, so CTCL-4 serum was not tested with it . None of the control
sera bound to HTLVcR as significantly as these two sera . The binding of patient CR
and CTCL-4 sera to HTLVcR compared with the mean binding of control sera was
20- and 12-fold greater, respectively . Whereas 75-fold dilutions of sera were used in
this survey, significant binding of both patient CR and CTCL-4 sera to HTLVcR
could easily be detected at dilutions of 1 :10,000. CTCL-4 serum was obtained from
a patient with Sezary syndrome, a T cell leukemia. A sufficient amount of this serum
was available for demonstrating the copurification of the antiviral reactivity with the
IgG fraction after elution from a DEAE cellulose column (35 ; data not shown) .
A wide variety of other antiviral reactivities was also seen in patient and control
sera (Table I) . We show below that the apparent cross-reactivities to animal type C
retroviruses, including BaEV, SSV, GaLV, RLV, and FeLV proteins are not viral
specific and are therefore probably artifacts . Recent reports have shown that the bulk
of and perhaps all human serum antibody reactivities to animal RNA tumor viruses
can be traced to either a fetal calfantigen that copurifies with the virus or to antigenic
components that are appended to the virus by the cell in which the virus is grown
(15-17) . In this initial report, we chose to examine the broad spectrum of antiviral
rectivities and to determine whether natural antibody specific forHTLVcR existed by
focusing only on the two serum samples (patient CR and CTCL-4) that reacted
strongly with HTLVcR.
Specificity of Serologic Reactivity to HTLVcR.
￿
The specificity of the serologic reactiv-
ities observed was first investigated using a solid-phase immunocompetition assay that
allowed us to test reactivity against several viral preparations at an equivalent level
of sensitivity after iodination of a single stable probe . This assay avoided exposure of
virus to strong oxidants, such a chloramine T, which may destroy antigenic sites . In
addition, short incubation times minimized protease digestion .
The reactivities of patient CR serum and CTCL-4 serum were remarkably specificPOSNER ET AL.
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TABLE I
Serologic Reactivity to HTLVGR and Other RNA Tumor Viruses in Patients with Cutaneous T Cell
Lymphomas and Leukemias and in Normal Individuals
' AMV background values not subtracted.
Serologic reactivity of patient CR serum to HTLVmB.
§ Mean value of55 normal sera including the 20 shown here, ± SD.
~~ Not done on all 55 normal sera.
for HTLVGR, and in the one case tested, patient CR, also specific for HTLVMB. These
reactivities could be competed only by HTLVGR or HTLVMB, and not by a variety
of other solubilized viral preparations, including the primate type C viruses BaEV,
GALV, and SSV (Fig. la and b). The specificity was further verified using protein
extracts of cells in similar competition assays. Lysates of HUT 102 cells, one of the cell
lines that produces HTLVGR, competed the reactivity of patient CR serum to
HTLVGR. There was no significant competiton with othercell lysates, including those
from normal human T cells; from established normal or transformed human B cell
lines; from established transformed immature T blast cell lines; or from HUT78 cells,
Serum HTLVGR BoLV FeLV M7 SSV GALV RLV (AMV) BSA- FCS'
Patient sera
Patient CR 8,217 282 795 4,930 190 194 558 (560) 385 268
5,788$
CTCL-2 0 0 0 0 0 0 0 (643) 265 229
CTCL-3 127 0 73 0 215 106 224 (563) 289 320
CTCL-4 5,295 503 1,685 1,726 1,659 2,841 1,952 (611) 280 306
CTCL-5 211 607 0 36 134 235 343 (535) 328 265
CTCL-6 1,023 385 700 406 1,034 974 836 (590) 281 351
CTCL-7 0 130 0 0 0 0 0 (437) 299 216
CTCL-8 898 392 1,232 188 1,284 1,731 1,431 (632) 272 234
CTCL-9 315 5 169 0 145 159 51 (563) 289 204
CTCL-10 462 123 464 46 216 252 688 (502) 291 230
CTCL-11 1,607 868 1,430 653 2,512 2,913 1,613 (559) 451 406
CTCL-12 984 1,526 2,560 1,702 3,972 3,930 2,565 (510) 376 373
CTCL-13 442 270 175 73 237 156 575 (323) 256 265
CTCL-14 198 63 54 0 265 163 203 (507) 356 363
CTCL-15 24 0 189 0 64 0 822 (839) 296 414
CTCL-16 291 55 370 7 385 246 782 (440) 330 224
CTCL-17 5,403 716 1,402 1,196 1,434 1,655 1,635 (494) 223 351
CTCL-18 405 0 386 0 242 353 548 (531) 226 240
Normal sera
1 2 0 0 0 135 36 78 (590) 286 196
2 0 361 671 142 1,000 851 845 (559) 329 203
3 0 0 0 0 221 207 0 (544) 246 224
4 54 64 79 0 148 108 225 (441) 318 233
5 151 378 57 12 269 318 243 (317) 326 186
6 363 233 82 0 241 309 0 (494) 208 215
7 394 326 1,319 0 693 1,600 1,161 (1,444) 387 359
8 165 62 410 0 149 868 493 (1,119) 359 394
9 259 39 330 101 484 377 681 (471) 209 185
to 0 0 410 171 533 360 626 (799) 368 281
11 127 102 304 0 404 211 624 (631) 195 185
12 602 319 982 248 1,363 1,338 1,464 (517) 260 310
13 652 292 734 0 880 964 1,234 (1,226) 367 460
14 477 459 531 37 652 914 1,385 (1,206) 513 539
15 726 395 250 0 499 738 43 (635) 199 196
16 0 6 0 0 0 0 191 (814) 214 237
17 741 463 558 388 935 1,297 779 (551) 211 190
18 375 271 570 43 1,213 822 1,190 (472) 188 155
19 0 0 0 0 24 0 134 (817) 170 222
20 59 53 24 163 109 378 108 (614) 194 172
Mean§ 380 153 563 136 NDJJ 664 789 876 510 ND
(±413) (±201) (±611) (±246) (3714) (±719) (±489) (:716)338
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punog VNId3 12101 %a transformed cell line established from cells of another patient with cutaneous T cell
lymphoma but not producing HTLV (Fig. lc) . In addition, competition with up to
1 mg of BSA or FCS failed to diminish binding of either CTCL-4 serum or patient
CR serum to HTLVcR (Fig. lb and c) .
Identification ofInvolved Proteins and Confirmation ofAnti-HTLVSpecificity.
￿
To identify
the proteins of HTLVcR responsible for the reactivities observed with the patient CR
and CTCL-4 sera, we developed an RIP assay against the proteins of the solubilized
virus. We have performed these experiments with both CTCL-4 and patient CR sera
with the same results, but only results with the latter are shown. The patient CR
serum recognized HTLVcR proteins with molecular weights of 24,000 and 19,000
(Fig. 2a and b) . A control serum from a normal donor failed to precipitate any
HTLVcR proteins. These two proteins, p24 and p19, have previously been identified
as components of HTLVcR and appear to be components of the viral core (27) . The
evidence for this is that (a) they copurify with the HTLVcR particles and cores; (b)
they can be identified when preparations of the solubilized HTLVcR proteins and not
the intact virus are radiolabeled; (c) in the case of p24, the protein elutes from
phosphocellulose in a manner similar to known viral p30 core proteins ; (d) the p24
migrates with reverse transcriptase activity with a density of intact virions and shifts
to a density of viral cores when the virus is treated with detergent ; and (e) these
proteins are readily detected in virus-producing transformed T cells but not in normal
growing human cells, including T cells, until the cells are infected in the laboratory.
Because the patient CR serum precipitated p24 and p19 of HTLVcR, we developed
a competition RIP assay against HTLVcR to confirm the results of the solid-phase
0
x
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a
U
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FIG. 2. Sodium dodecylsulfate-polyacrylamide gel electrophoresis of iodinated proteins of
HTLVcR (a) and immune precipitates obtained using serum from patient CR or normal control
serum and iodinated proteins of HTLVcR (b). The immune precipitates in (b) contained nearly
equivalent counts of
i
51 and were obtained using either patient CR serum (" ) or normal serum
(O).340
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immunocompetition assay. We were able to use greater amounts of competing viral
protein in the expanded volumes of the RIP assay to confirm the specificity of the
natural antibody response to HTLVcR . The results of the RIP competition failed to
demonstrate significant homology between the HTLVcR p 19 or p24 and the proteins
of any other virus tested (Fig . 3a) . Only HTLVcR effectively inhibited HTLVcR
precipitation over the range of protein concentrations tested . Similarly, when cell
lysates were used in the compeition assays, only the HTLVcR-producing HUT102
cells were able to compete the precipitation ofHTLVcR proteins (Fig. 3b) .
Lack ofSpecificity ofSerologic Reactivities to AnimalRNA Tumor Viruses.
￿
We next turned
our attention to the apparent cross-reactivities of patient CR and CTCL-4 sera with
BaEV and of CTCL-4 with both the woolly monkey-gibbon ape retroviruses and
FeLV (Table I) . Solid-phase immunocompetition assays were carried out to determine
the specificity of these reactivities (Fig. 4) .
The binding of patient CR serum to BaEV could be reduced by preincubation
with BaEV, strain M7, grown in A204 cells (M7/A204), with RD114, and at high
concentrations with HTLVcR (Fig . 4A) . Similar data were obtained using CTCL-4
serum (not shown) . The competition by HTLVcR was unidirectional, i .e ., HTLVcR
could reduce the binding of patient CR and CTCL-4 sera to M7/A204, but preab-
sorbing either serum sample with M7/A204 could not reduce binding to HTLVcR
(Fig . 4A and B) . This result cannot be explained by a single cross-reactive viral
determinant present in greater quantity in HTLVcR than in M7/A204 . If this were
the case, HTLVcR should reduce the serum reactivity to M7/A204 at a significantly
lower concentration than M7/A204 itself, exactly opposite to what is found (Fig. 4) .
In addition, the reactivity of patient CR serum (and CTCL-4 serum) to M7/A204
could not be competed by BaEV grown in canine thymus cells (M7/A7573), suggest-
ing that the reactive antigen from M7/A204 is cellular and not viral in origin .
Barbacid et al . (15) have suggested that 1% BSA will preabsorb human natural
antibodies directed toward animal RNA tumor viral proteins . The fact that our
buffers did not include BSA does not affect our results because the cross-reactivity
T HTLV,R
D BoLV
A SSV
o GaLVSF
FeLV
0 AMV
A M7/A204
o RLV
Micrograms of Competing Protein (viral)
100
-°HUT 102
m-0-0-0 Q-06-0L-0
0 HUT 78
￿
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￿
0
O Normal T Cells
4 Deudi
o Mole 4
A204
CEM
0 RSA
AFCS
a
°\n v
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￿
100 200
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Micrograms of Competing Cellular Protein
Fic . 3 .
￿
Competition radioimmunoprecipitation assay ofpatientCR serum against solubilized viral
preparations (a) and cell lysates (b) .POSNER ET AL.
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described is only found when the virus of interest is grown in nonhuman cells (15) .
This is not the case with HTLVcR, HTLVMB, or M7/A204, which are all grown in
human cells . However, to erase any doubts as to the presence of BSA or FCS shared
determinants, immunocompetition assays were carried out using BSA or FCS as
competitors . Neither one competed the observed binding to M7/A204 (Fig . 4A) .
These data suggest no homology between HTLVcR and BaEV . This conclusion
was verified by molecular hybridization studies (26), by competition radioimmunoas-
says using various viral core proteins (p30) and HTLVcR p24 (27), and by comparisons
of the cross-reactivity of the reverse transcriptase of HTLV and that of other
retroviruses (28) . All tests failed to show any relationship between HTLV and BaEV .
The results indicate therefore that whereas patient CR serum reactivity to BaEV is
probably directed against a cellular antigen, its reactivity to HTLV is clearly viral
specific .
The CTCL-4 serum was the only one identified that reacted with the primate
viruses of the woolly monkey-gibbon ape group, with RLV and FeLV, as well as with
HTLVcRand BaEV (Table 1) . Solid-phase immunocompetition studies revealed that
binding to GALVSF could be completely inhibited by preabsorption with high
concentrations of FCS (Fig . 4B) . No inhibition of binding occurred with purified
BSA . This parallels the data of Snyder et al . (16, 36) who found that the apparent
specificity of human antibodies for the gp70 ofSSV was in fact cross-reactive with a
carbohydrate antigen present in FCS .
The binding of CTCL-4 serum to FeLV (Table 1) was also nonspecific . The
reactivity could be reduced to 50% after incubation with FCS, whereas preincubation
with the same FeLV preparation present on the solid phase could reduce binding to
<25% ofmaximum (Fig . 4) . This indicates that an antigen associated with the FeLV
preparation cross-reactive with a fetal calf antigen is partially responsible for the
reduction in serum binding and that a second distinct antigen is also present . We do
not know if the latter antigen is viral or cellular in origin .
The identification of the reactive antigen in FeLV or GALVSF is not the purpose
of this publication . These relationships were explored with the CTCL-4 serum to show
that they were distinct from the viral-specific cross-reactivity of both patient CR and
CTCL-4 sera for HTLVcR. By inference, however, one may conclude that the wide
variety of reactivities present in patient and control sera (Table 1) directed toward
FeLV, GALV, and the related viruses SSV and RLV, share the same lack of
specificity.
Discussion
The HTLV are new retroviruses not yet detectably related to known animal
retroviruses . These viruses were isolated from cells of different patients, one with a
cutaneous T cell lymphoma, the other with a cutaneous T cell leukemia . There were
strong arguments that the HTLV isolates were not contaminants : (a) the repeated
detection of viral particles in different clinical specimens of patient CR ; (b) the
detection of viral particles within the first few days ofputting the primary tumor cells
in culture ; and (c) the lack of a close relationship to other known animal retroviruses,
as with the bovine leukemia virus . However, it was still important to determine
whether HTLV could be detected in vivo . This has now been accomplished by two
different methodologies, including the demonstration of HTLV protein and nucleicPOSNER ET AL.
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acids in primary (uncultured) neoplastic T cells of a few patients,2 and the finding of
antibodies to HTLV in human sera as shown in this report and elsewhere. We are
aware that previously reported antibody responses toward purported animal viral
proteins subsequently have been shown to be nonspecific cross-reactions . Therefore,
detection of a reactivity against a viral protein may not verify an in vivo infection .
Others have shown (15-17), and we were able to confirm with respect to primate and
feline retroviruses that such reactivities may be devoid of viral specificity . However,
the data shown here regarding HTLV, isolated from the lymph node-derived cell line
of patient CR, are the first to unequivocally demonstrate antibodies from human sera
with a high degree of specificity for retroviral antigens. We used a plate competition
assay that demonstrated that patient CR serum was specific for HTLVcR and
HTLVMB proteins and that the antigens recognized were not cross-reactive with those
ofany commonly encountered retroviruses . The results of the solid-phase assay agreed
completely with the RIP competition studies performed against disrupted HTLVcR,
substantiating the specificity of the natural antibodies and the uniqueness of the
HTLVcR determinants . The antibodies present recognized core proteins that would
be expected if the virus were truly replicating in vivo . Data reported elsewhere show
that the same patient CR and CTCL-4 sera possess antibodies to homogeneously
purified HTLV p24, the major core protein of the virus.
Antibodies to HTLV have not been detected in the majority of patients with
cutaneousT cell leukemias and lymphomas studied to data . However, from experience
gained from animal models (37, 38), it is clear that the absence of antibodies in a
given patient does not necessarily mean that HTLV never infected these people .
Cellular transformation may be more common than virus production, and antibodies
will not be produced unless viral proteins are expressed . It is also possible that
HTLVcR expression may be associated only with pathologic subsets ofCTCL, such
as those with peripheral blood or visceral involvement . A much more extensive study
using sera from patients with CTCL and other T cell neoplasias, and normal donors
is clearly needed now to gain information on the natural virus reservoir and its mode
of transmission .
Summary
Sera from patients with cutaneous T cell lymphoma and leukemia were screened
for the presence of natural antibody to the human T cell lymphoma (leukemia) virus,
HTLVcR, using a solid-phase radioimmunoassay . Sera from two patients, including
patient CR, from whose cultured T lymphoblastic cell line (HUT102) the retrovirus
HTLVcR was isolated, reacted specifically with proteins of HTLVcR . Serum from
patient CR also reacted specifically with proteins of HTLVMB, an independent but
highly related retroviral isolate from a patient with Sezary T cell leukemia . The
specificity for HTLVcR proteins was demonstrated by solid-phase immunocompeti-
tion assays and competition radioimmunoprecipitation assays . Analysis of radioim-
munoprecipitates indicated that the natural antibodies were directed against HTLVcR
core proteins with molecular weights of 24,000 and 19,000 (p24 and p19) . Whereas
the serum reactivities for HTLVcR proteins were shown to be highly specific,
aKalyanaraman, V. S.,M. G. Sarngadharan, P . A . Bunn,J. D. Minna, and R. C. Gallo . Antibodies in
human sera reactive against an internal structural protein (p24) of humanTcell lymphoma virus (HTLV) .
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additional reactivities seen against proteins of animal retroviruses including GaLV,
SSV, FeLV, and BaEV were clearly shown not to be viral specific but rather were
due to reactivity with cellular antigens contaminating the viral preparations or with
related antigens present in fetal calf serum . These results demonstrating natural
antibodies to HTLVCR provide the first evidence for a specific antibody response to
a retrovirus in humans .
We gratefully acknowledge the excellent technical assistance of Ms . Kathy Fahey .
Receivedfor publication 25 March 1981 .
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